David S. Goldfarb MD
Director, Kidney Stone Prevention Program and Professor of Medicine & Physiology, NYU Grossman School of Medicine
Join to View Full Profile
222 E 41st StNew York, NY 10017
Phone+1 212-263-5851
Fax+1 212-434-6370
Dr. Goldfarb is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. David Goldfarb is a nephrologist in New York, NY and is affiliated with VA NY Harbor Healthcare System, Manhattan Campus and NYU Langone Hospitals. He received his medical degree from Yale University School of Medicine and has been in practice 36 years. He is experienced in cystinuria, medullary sponge kidney, nephrolithiasis, Dent disease, CKD, ESKD, COVID-19 and gout.
Education & Training
NYU Grossman School of MedicineFellowship, Nephrology, 1985 - 1987- NYU Grossman School of Medicine (Veterans)Residency, Internal Medicine, 1981 - 1985
Yale School of MedicineClass of 1981
Certifications & Licensure
NY State Medical License 1983 - 2028
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Nephrology
Awards, Honors, & Recognition
- Fellow (FASN) American Society of Nephrology
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2015-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2015-2017
Clinical Trials
- The Effects of Sports Drinks on Urinary Lithogenicity Start of enrollment: 2006 Mar 01
- Rare Kidney Stone Consortium Patient Registry
- Effect of Sodium Thiosulfate on Urine Chemistries of Hypercalciuric Stone Formers Start of enrollment: 2009 Nov 01
Publications & Presentations
PubMed
- 37 citationsCystinuria: an update on pathophysiology, genetics, and clinical managementViola D’Ambrosio, Giovanna Capolongo, David S. Goldfarb, Giovanni Gambaro, Pietro Manuel Ferraro
Pediatric Nephrology. 2021-11-23 - 8 citationsRecommendations from the EXTRIP workgroup on extracorporeal treatment for baclofen poisoning.Marc Ghannoum, Ingrid Berling, Valery Lavergne, Darren M. Roberts, Taís Freire Galvão
Kidney International. 2021-10-01 - 12 citationsFeasibility and Acceptability of mHealth Interventions for Managing Hyperphosphatemia in Patients Undergoing Hemodialysis.David E. St-Jules, Kathleen Woolf, David S. Goldfarb, Mary Lou Pompeii, Huilin Li
Journal of Renal Nutrition. 2021-07-01
Other
- Opioid Overuse or NSAID Underuse? A Response to the Pain GuideDavid Goldfarb, MD, American Journal of Kidney Diseases
https://www.doximity.com/articles/f5536f97-56ab-4efb-8c6e-3feb55264fa5
UpToDate, Wolters Kluwer Health - 2012-05-15
Press Mentions
SGLT2 Inhibitors Might Lower Stone Risk Better Than Other Type 2 Diabetes DrugsMarch 12th, 2025- NYU Langone Health in the News—Wednesday, January 8, 2025January 8th, 2025
- SGLT2 Inhibitors Might Lower Stone Risk Better Than Other Type 2 Diabetes DrugsNovember 15th, 2024
Grant Support
- CystinuriaNational Institute Of Diabetes And Digestive And Kidney Diseases2009–2011
Committees
- Vice-chair, American Urological Association, Medical Management of Kidney Stones 2013 - 2014
Professional Memberships
- Fellow
- Member
- Member
Industry Relationships
- Consultant, Travere2014 - Present
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
